Global Infertility Market 2015-2019

不妊症治療薬・装置の世界市場2015-2019

◆タイトル:Global Infertility Market 2015-2019
◆商品コード:IRTNTR5289
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年2月18日
◆ページ数:92
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、不妊症治療薬・装置の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、不妊症治療薬・装置の世界市場規模及び予測、種類別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Infertility
Infertility is a widespread problem, and it is the inability to conceive after having regular unprotected sex. In one-third of the cases, infertility is because of either female infertility factors or male infertility factors. In rest of the cases, the cause is either unknown or a combination of both male and female factors. In males, infertility is due to a couple of factors including low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm. The cause of infertility can be difficult to diagnose, but many treatments are available. Treatment options depend on underlying problems.

TechNavio’s analysts forecast the Global Infertility market to grow at a CAGR of 4.52 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Infertility market for the period 2015-2019. The Global Infertility market can be divided into two segments: Infertility Drugs and Infertility Devices. To calculate the market size, the report considers revenue generated from the sales of various drugs and devices used in the treatment of infertility.

TechNavio’s report, the Global Infertility Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Infertility market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Bayer Healthcare
• CooperSurgical
• Ferring Pharmaceuticals
• Merck & Co.

[Other Prominent Vendors]
• Abbott Laboratories
• AbbVie
• Actavis
• Apricus Biosciences
• AstraZeneca
• Bristol-Myers Squibb
• Dong-A Socio
• Elelixis Diagnostics
• Eli Lily
• Halotech DNA
• HRA Pharma
• Invo Bioscience
• Medical Electronic Systems
• Novartis
• Pfizer
• PregLem
• Sanofi
• Vivus

[Market Driver]
• Increase in Aging Population
• For a full, detailed list, view our report

[Market Challenge]
• Patent Expires of Major Blockbuster Drugs
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Etiology
06.1.1 Male Infertility Etiology
06.1.2 Pre-testicular
06.1.3 Testicular
06.1.4 Post-testicular
06.1.5 Others
06.1.6 Female Infertility Etiology
06.1.7 Female Infertility associated with Anovulation
06.1.8 Female Infertility of Tubal Origin
06.1.9 Female Infertility of Uterine Origin
06.1.10 Female Infertility of Other Origin
06.1.11 Female Infertility, Unspecified
06.2 Signs and Symptoms
06.2.1 Male Infertility Signs and Symptoms
06.2.2 Female Infertility Signs and Symptoms
06.3 Treatment
06.3.1 Treatment for Male Infertility
06.3.2 Treatment for Female Infertility
06.3.3 Reproductive Assistance
06.4 Tests and Diagnosis
06.4.1 Male: Tests and Diagnosis
06.4.2 Female: Tests and Diagnosis
06.4.3 Prevalence

07.Country Overview
07.1.1 US
07.1.2 UK

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Type
09.1.1 Infertility Drugs
09.1.2 Infertility Devices
09.2 Global Infertility Drugs Market
09.2.1 Market Size and Forecast
09.3 Global Infertility Devices Market
09.3.1 Market Size and Forecast

10.Market Segmentation by Underlying Cause

11.Geographical Segmentation
11.1 Infertility Market in Americas
11.1.1 Market Size and Forecast
11.2 Infertility Market in APAC Region
11.2.1 Market Size and Forecast
11.3 Infertility Market in EMEA Region
11.3.1 Market Size and Forecast

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Licensing and Collaborations
19.1.3 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.3 Other Prominent Vendors

20.Key Vendor Analysis
20.1 Bayer HealthCare
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2013
20.1.4 Business Segmentation by Revenue 2012 and 2013
20.1.5 Geographical Segmentation by Revenue 2013
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 CooperSurgical
20.2.1 Key Facts
20.2.2 Business Description
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue
20.2.5 Business Segmentation by Revenue 2012 and 2013
20.2.6 Business Strategy
20.2.7 Key Developments
20.2.8 SWOT Analysis
20.3 Ferring Pharmaceuticals
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 SWOT Analysis
20.4 Merck & Co. Inc.
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Business Segmentation by Revenue 2013
20.4.4 Business Segmentation by Revenue 2012 and 2013
20.4.5 Sales by Geography
20.4.6 Business Strategy
20.4.7 Key Developments
20.4.8 SWOT Analysis

21.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Etiology of Male Infertility
Exhibit 3: Etiology of Female Infertility
Exhibit 4: Treatment of Male Infertility
Exhibit 5: Diagnosis of Male Infertility
Exhibit 6: Factors Affecting Infertility in 2014 (Global)
Exhibit 7: Percentage of Primary and Secondary Infertility in 2010 (Global)
Exhibit 8: Percentage of Married Infertile Women with Primary Infertility: US, 1965–2010
Exhibit 9: Causes of Infertility in US
Exhibit 10: Increasing Prevalence of Infertility of Women (various age-groups in year) in UK 2009
Exhibit 11: Causes of Infertility in UK 2009
Exhibit 12: Global Infertility Market 2014-2019 (US$ million)
Exhibit 13: Segmentation of Global Infertility Market by Type
Exhibit 14: Global Infertility Drugs Market 2014-2019 (US$ million)
Exhibit 15: Global Infertility Devices Market 2014-2019 (US$ million)
Exhibit 16: Global infertility market by drugs & devices in 2014 and 2019 (US$ million)
Exhibit 17: Global Infertility Market Segmentation by Type 2014
Exhibit 18: Global Infertility Market Segmentation by Type 2019
Exhibit 19: Global Infertility Market 2014-2019 (US$ million)
Exhibit 20: Segmentation of Global Infertility Market by Underlying Cause
Exhibit 21: Global Infertility Market by Geographical Segmentation 2014
Exhibit 22: Infertility Market in Americas 2014-2019 (US$ million)
Exhibit 23: Infertility Market in APAC region 2014-2019 (US$ million)
Exhibit 24: Infertility Market in EMEA Region 2014-2019 (US$ million)
Exhibit 25: Global infertility market by region in 2014 and 2019 (US$ million)
Exhibit 26: CooperSurgical: YoY Sales Comparison 2010-2013 (US$ million)
Exhibit 27: Merck’s Gonal-f YoY Sales Comparison 2011-2013 (US$ million)
Exhibit 28: Bayer HealthCare: Business Segmentation by Revenue 2013
Exhibit 29: Bayer HealthCare: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 30: Bayer HealthCare: Geographical Segmentation by Revenue 2013
Exhibit 31: CooperSurgical: Business Segmentation 2013
Exhibit 32: CooperSurgical: Business Segmentation by Revenue 2013
Exhibit 33: CooperSurgical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 34: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 35: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 36: Merck & Co. Inc.: Sales by Geography 2013



【掲載企業】

Bayer Healthcare , CooperSurgical, Ferring Pharmaceuticals, Merck & Co., Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Bristol-Myers Squibb, Dong-A Socio, Elelixis Diagnostics, Eli Lily, Halotech DNA, HRA Pharma, InvoBioscience, Medical Electronic Systems, Novartis, Pfizer, PregLem, Sanofi, Vivus

【資料のキーワード】

不妊症治療薬(妊娠促進薬)、治療装置(デバイス)、医療機器、医薬品、女性不妊症、男性不妊症

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[不妊症治療薬・装置の世界市場2015-2019] (Global Infertility Market 2015-2019 / IRTNTR5289)販売に関する免責事項
[不妊症治療薬・装置の世界市場2015-2019] (Global Infertility Market 2015-2019 / IRTNTR5289)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆